Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
26.92
-1.10 (-3.93%)
At close: May 19, 2026, 4:00 PM EDT
26.80
-0.12 (-0.43%)
Pre-market: May 20, 2026, 7:22 AM EDT
Capricor Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
231
Market Cap
1.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | 1.01M | -666.33K | -39.87% |
| Dec 31, 2018 | 1.67M | -994.98K | -37.32% |
| Dec 31, 2017 | 2.67M | -1.33M | -33.32% |
| Dec 31, 2016 | 4.00M | -1.52M | -27.53% |
| Dec 31, 2015 | 5.52M | 730.95K | 15.27% |
| Dec 31, 2014 | 4.79M | 4.28M | 851.19% |
| Dec 31, 2013 | 503.23K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 1.35M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 427.68M |
| Innoviva | 420.69M |
| Iovance Biotherapeutics | 285.61M |
| Nurix Therapeutics | 71.78M |
| Recursion Pharmaceuticals | 66.41M |
| Generate Biomedicines | 30.30M |
| uniQure | 18.09M |
| Taysha Gene Therapies | 7.47M |
CAPR News
- 5 days ago - Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital - TheFly
- 7 days ago - Capricor Therapeutics Q1 Earnings Call Highlights - MarketBeat
- 7 days ago - Capricor Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 7 days ago - Capricor Therapeutics Earnings release: Q1 2026 - Filings
- 7 days ago - Capricor Therapeutics Quarterly report: Q1 2026 - Filings
- 7 days ago - Capricor Therapeutics options imply 9.4% move in share price post-earnings - TheFly
- 7 days ago - Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 days ago - Capricor files suit against NS Pharma over Deramiocel distribution deal - TheFly